Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2019 08:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Data Presentation at the Upcoming American Academy of Neurology 71st Annual Meeting

NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the Phase 2 multicenter trial evaluating ublituximab (TG-1101), the Company’s novel...
March 11, 2019 07:26 ET | Source: TG Therapeutics, Inc.

TG Therapeutics to Present at the Cowen 39th Annual Health Care Conference

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will present...
March 08, 2019 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Positive Data Safety Monitoring Board Reviews of UNITY-CLL and UNITY-NHL Clinical Trials

UNITY-CLL DSMB conducted a pre-planned futility analysis of progression-free survival, and determined that the study was not futile and should continue as planned No safety concerns identified by the...
March 01, 2019 09:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Approximately $85 million in Equity and Debt Financings

NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases, today announced...
March 01, 2019 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Final Phase 2 Multiple Sclerosis Data Presentation at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting

NEW YORK, March 01, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today...
February 28, 2019 16:01 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Proposed Public Offering of Common Stock and Closing of $60.0 Million Venture Debt Financing

NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today...
February 28, 2019 07:00 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Positive Outcome from UNITY-NHL Phase 2b Pivotal Trial Evaluating Umbralisib in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Study met the primary endpoint of Overall Response Rate (ORR) Interim data to be presented in an oral presentation at the 2019 American Association of Cancer Research (AACR) annual meeting on April...
February 26, 2019 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics Announces Initiation of Phase I First-in-Human Clinical Trial of its Anti-CD47/CD19 Bispecific Antibody, TG-1801, in Patients with Relapsed or Refractory B-cell Lymphoma

NEW YORK, Feb. 26, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today...
February 22, 2019 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting

NEW YORK, Feb. 22, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the final Phase 2 data from the multicenter trial of ublituximab (TG-1101), the Company’s novel...
January 30, 2019 07:30 ET | Source: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase I Triple Therapy Combination Trial of Ublituximab, Umbralisib, and Ibrutinib in The Lancet Haematology

NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of results from the multicenter Phase 1 triple combination trial of ublituximab...